Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

State auditors flagged mismanagement and political influence in AICS and AKAP, yet the bicameral committee still approved ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

The program, included in President Donald Trump’s “Big Beautiful Bill,” offers a generous tax incentive to people who donate to scholarship organizations.

From a global regulatory perspective, Cytokinetics is expanding its footprint rapidly. The drug received approval in China on ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Research shows that live musical performances in hospitals benefit the physical and emotional well-being of patients, their ...

ESET researchers provide a comprehensive analysis and assessment of a critical severity vulnerability with low likelihood of ...

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, ...

Cybersecurity protection is a C-suite issue that is so fast-changing and technical, it’s hard for CEOs to properly manage.

Thyroid disorders, common endocrine conditions, often require long-term management. Shivkumar Aggarwal, seeking lasting ...

Todd Golden was largely pleased with his team's performance in a 30-point win over Colgate on Sunday. Here's what he said ...